Postherpetic Neuralgia
📧 Sign up to get email alerts when something new happens for Postherpetic Neuralgia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2012-03-23FDA Approved: GABAPENTIN — Original Application (Amneal Pharmaceuticals LLC)
The FDA approved Amneal Pharmaceuticals' original Abbreviated New Drug Application for gabapentin, authorizing a generic gabapentin product.
-
CLINICAL_TRIALS trial_result · 2012-02-02Clinical Trial Update: Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia [Phase 2, Phase 3]
A completed Phase 2/3 trial evaluated the efficacy, safety and tolerability of TAK-583 in subjects with postherpetic neuralgia.
-
FDA approval · 2012-01-31FDA Approved: GRALISE — Supplemental Application (Almatica Pharma LLC)
The FDA approved a supplemental application for GRALISE (gabapentin) filed by Almatica Pharma LLC.
-
CLINICAL_TRIALS trial_result · 2012-01-30Clinical Trial Update: Impact of Neuropathic Post-Zosterian Pain on the Cognition
A completed clinical trial evaluating whether neuropathic post-zosterian pain impacts cognitive function.
-
CLINICAL_TRIALS trial_result · 2012-01-13Clinical Trial Update: Safety and Efficacy of Gabapentin in Postherpetic Neuralgia [Phase 3]
Phase 3 clinical trial evaluating the safety and efficacy of gabapentin for postherpetic neuralgia; results have been posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-01-11Clinical Trial Update: Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN) [Phase 2]
Phase 2 safety/efficacy study comparing retigabine (ezogabine) to placebo for postherpetic neuralgia; results were posted in 2012.
-
FDA approval · 2011-11-25FDA Approved: GABAPENTIN — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for gabapentin submitted by BluePoint Laboratories.
-
FDA approval · 2011-09-29FDA Approved: GABAPENTIN — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for Gabapentin submitted by BluePoint Laboratories.
-
CLINICAL_TRIALS trial_result · 2011-08-31Clinical Trial Update: New Topical Treatment for Continued Pain After Shingles [Phase 1]
Phase 1 clinical trial update reports completion of testing for a new topical treatment intended to relieve persistent pain after shingles (…
-
FDA approval · 2011-08-30FDA Approved: GABAPENTIN — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for gabapentin submitted by Zydus Pharmaceuticals USA Inc.
-
FDA approval · 2011-08-30FDA Approved: GABAPENTIN — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Gabapentin from Aurobindo Pharma Limited under an approved ANDA.
-
FDA approval · 2011-08-29FDA Approved: GABAPENTIN — Supplemental Application (Exelan Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Gabapentin from Exelan Pharmaceuticals, Inc. (ANDA 090705).
-
FDA approval · 2011-08-29FDA Approved: GABAPENTIN — Supplemental Application (BluePoint Laboratories)
FDA approves a supplemental application for Gabapentin from BluePoint Laboratories, updating the existing approval for the generic product.
-
FDA label_change · 2011-08-29FDA Approved: GABAPENTIN — Supplemental Application (Granules Pharmaceuticals Inc)
FDA approved a Gabapentin supplemental application from Granules Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2011-08-23Clinical Trial Update: Study to Evaluate the Safety and Analgesic Activity of ATx08-001 in Subjects With Postherpetic Neuralgia [Phase 2]
A Phase 2 study evaluating the safety and analgesic activity of ATx08-001 in subjects with postherpetic neuralgia has completed.
-
FDA approval · 2011-07-21FDA Approved: GABAPENTIN — Original Application (TIME CAP LABORATORIES, INC)
FDA approved gabapentin as a generic drug under an Original Application submitted by Time Cap Laboratories, Inc. This approval enables marke…
-
FDA approval · 2011-07-14FDA Approved: GABAPENTIN — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for gabapentin submitted by Ascend Laboratories, LLC.
-
CLINICAL_TRIALS trial_result · 2011-07-06Clinical Trial Update: A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN) [Phase 2]
A Phase 2 trial comparing EpiCept NP-1 topical cream with oral gabapentin in postherpetic neuralgia has been completed, with results posted …
-
FDA approval · 2011-06-28FDA Approved: GRALISE — Supplemental Application (Almatica Pharma LLC)
The FDA approved a supplemental application for Gralise (gabapentin) from Almatica Pharma LLC.
-
FDA approval · 2011-06-20FDA Approved: LYRICA — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for LYRICA (pregabalin) submitted by Parke-Davis Div of Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2011-05-30Clinical Trial Update: A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia [Phase 2]
A Phase 2 trial evaluating botulinum toxin type A for postherpetic neuralgia has completed.
-
CLINICAL_TRIALS trial_result · 2011-05-20Clinical Trial Update: A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN) [Phase 2]
Phase 2 clinical trial in patients with neuropathic pain from post-herpetic neuralgia has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2011-05-20Clinical Trial Update: A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment [Phase 2]
Phase 2 clinical study in postherpetic neuralgia patients who had an inadequate response to gabapentin; results were posted in 2011.
-
CLINICAL_TRIALS trial_result · 2011-05-16Clinical Trial Update: PH-797804 Versus Placebo For The Treatment Of Neuropathic Pain Associated With Post-Herpetic Neuralgia [Phase 2]
Phase 2 randomized trial comparing PH-797804 to placebo for neuropathic pain in postherpetic neuralgia has completed.
-
FDA approval · 2011-04-26FDA Approved: LYRICA — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for LYRICA (pregabalin) filed by Parke-Davis Div of Pfizer Inc.